Nasdaq
$5.27▲ 1.93%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $84.0MShares out 15.9M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
13- 10.15Pre-market26.10.15 20:008-KKey event#●●●#●●●
Tonix Pharmaceuticals Holding Corp.
Tonix Pharmaceuticals announced preliminary operating results for the third quarter of 2026, estimating net revenue for TONMYA to be between $14.0 million and $15.0 million. As of September 30, 2026, the company's cash and cash equivalents are estimated to be approximately $162.8 million.…more
$5.27+1.93%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 10.2After-hours26.10.03 06:208-KKey event
Tonix Pharmaceuticals Holding Corp.
Tonix Pharmaceuticals received a Paragraph IV notice from Dr. Reddy's Laboratories regarding an Abbreviated New Drug Application (ANDA) for a generic version of its drug, TONMYA. The company intends to vigorously enforce its four Orange Book-listed patents, though the outcome of potential patent litigation remains uncertain.…more
$5.27+1.93%vs prev closeView filingShare - 9.22Pre-market26.09.22 20:058-KKey event
Tonix Pharmaceuticals Holding Corp.
Tonix Pharmaceuticals has secured a second major managed Medicare agreement for its fibromyalgia treatment, TONMYA, effective immediately. This agreement adds approximately 21 million Medicare beneficiaries, bringing the total U.S. commercial and government payer coverage for the drug to approximately 166 million individuals.…more
$5.27+1.93%vs prev closeView filingShare
12 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 6d agoPre-market26.10.19 20:14#●●●#●●●
Tonix Pharmaceuticals to Present Data on Fibromyalgia Drug TONMYA at World Congress on Pain…more
Tonix Pharmaceuticals will present clinical data regarding the physical symptom and functional improvements of its FDA-approved fibromyalgia treatment, TONMYA. As the drug is already commercially available, this presentation serves as an academic update on its therapeutic efficacy.…more
$5.27+1.93%vs prev closeDetected5m · 30m · 60m · Next dayPLUSShareBenzinga
- 10.15Pre-market26.10.15 20:00
●●●●●●●● ●●●●● ●●●●●●
Tonix Pharmaceuticals announced it will present data on its TNX-801 vaccine platform for mpox and other infectious diseases at the upcoming World Vaccine Congress Europe. This event is academic in nature and does not represent a material clinical milestone or immediate financial catalyst for the company.…more
$5.27+1.93%vs prev close - 10.2After-hours26.10.03 06:32
●●●●●●●● ●●●●● ●●●●●●
Dr. Reddy's Laboratories has filed an ANDA with a Paragraph IV certification to challenge the patents of Tonix's TONMYA. Tonix intends to vigorously enforce its intellectual property rights against this generic challenge.…more
$5.27+1.93%vs prev closeShareBenzinga
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report